MISSISSAUGA, Ontario--(BUSINESS WIRE)--Jan. 28, 2019--
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV;
OTCQX: CVALF), an advanced medical technologies company, today announced
that Dr. Myrna Francis has joined Covalon’s Board of Directors.
Dr. Francis has an extensive background in healthcare and is well-known
in both private and public sectors; her experience spans the
international marketplace – Canada, the US, and Europe. She is currently
the President of Mfran Healthcare Advisory Services. She is the Vice
Chair of OCAD University’s Board of Governors and serves as a Board
Director at Medavie Inc. and as a volunteer advisor for BioMedical Zone
and MaRS Discovery District, Health Ventures Group. Dr. Francis has
previously held positions as the CEO of Canada Health Infoway, Vice
President, Global Healthcare Sector, at CGI Group Inc., Partner at CSC
Healthcare Group, and numerous executive positions with the Ontario
Ministry of Health. She has also served as a Board Director for a
variety of companies and organizations, including RxCanada, Allstate
Insurance Company of Canada, and Cedara Software Corp. She currently
provides strategic advisory services in the public sector and to
multinational private sector companies regarding health information
technology, business transformation, business and product growth
strategies, and innovation as an independent consultant. Dr. Francis
holds a Master’s Degree in Psychology and Ph.D. in Medical Sciences,
both from McMaster University, and a Multi-Party Negotiations
Certification from Harvard Law School.
“I am looking forward to serving on Covalon’s Board of Directors,” said
Dr. Francis. “I am familiar with Covalon’s management from my time as a
Director at Cedara Software and have watched Covalon grow over the last
few years. I am excited to participate in the guidance of this
successful and growing company.”
“Covalon is delighted to have someone of Dr. Francis’ experience join
our Board of Directors,” said Brian Pedlar, Chief Executive Officer.
“Dr. Francis has significant experience in the healthcare industry and
with both public and private boards, developed during her impressive
career. The Covalon management team and board are looking forward to
benefiting from Dr. Francis’ contribution as an independent board
Dr. Francis’ appointment to Covalon’s Board of Directors is subject to
Covalon Technologies Ltd. researches, develops, and commercializes new
healthcare technologies that help save lives around the world. Covalon's
patented technologies, products, and services address the advanced
healthcare needs of medical device companies, healthcare providers, and
individual consumers. Covalon's technologies are used to prevent,
detect, and manage medical conditions in specialty areas such as
infection control, vascular access, surgical procedures, advanced wound
care, and medical device coatings. To learn more about Covalon, visit
our website at www.covalon.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect
the Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will", "should",
"could" or "might" occur or be achieved and other similar expressions.
These forward-looking statements involve risk and uncertainties,
including completion of integration of the AquaGuard acquisition, the
difficulty in predicting product approvals, acceptance of and demands
for new products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or achievements to
differ materially from the results discussed or implied in the
forward-looking statements. Many risks are inherent in the industry;
others are more specific to the Company. Investors should consult the
Company's ongoing quarterly filings for additional information on risks
and uncertainties relating to these forward-looking statements.
Investors should not place undue reliance on any forward-looking
statements. The Company assumes no obligation to update or alter any
forward-looking statements whether as a result of new information,
further events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190128005075/en/
Source: Covalon Technologies Ltd.
Brian Pedlar, CEO, Covalon Technologies Ltd.
905.568.8400 x 233
Toll free: 1.877.711.6055
Web site: www.covalon.com